Free Trial

The 12 Most-Hated Stocks on Wall Street - 12 of 12

 
 

Editas Medicine (NASDAQ:EDIT)

Number of Downgrades
18 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.1
Ratings Breakdown
3 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$7.00 (490.7% Upside)

About Editas Medicine

Editas Medicine logoEditas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
12/16/2024Evercore ISILower Price TargetOutperform ➝ Outperform$7.00 ➝ $5.00
12/16/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/13/2024Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
12/13/2024BarclaysLower Price TargetEqual Weight ➝ Equal Weight$5.00 ➝ $3.00
12/13/2024Chardan CapitalReiterated RatingBuy ➝ Neutral
12/13/2024Robert W. BairdLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.00
12/13/2024Stifel NicolausDowngradeBuy ➝ Hold$11.00 ➝ $3.00
12/13/2024Truist FinancialDowngradeBuy ➝ Hold
12/11/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$7.00 ➝ $4.00
11/25/2024Bank of AmericaDowngradeBuy ➝ Underperform$13.00 ➝ $1.00

More Investing Slideshows:

 

BITCOIN (Ad)

Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this...

Watch this short video